US2008214471A1PendingUtilityA1

Method for inhibition of viral infection

Individually held — no corporate assignee on recordPriority: May 29, 1992Filed: Aug 20, 2007Published: Sep 4, 2008
Est. expiryMay 29, 2012(expired)· nominal 20-yr term from priority
A61K 31/365C12Q 1/18C12N 7/00C12N 2770/24263C12Q 1/6897G01N 33/5097G01N 33/56983A61K 38/005A61P 43/00G01N 33/5008A61P 31/12G01N 33/5765G01N 33/502C12N 2770/24222C07K 14/005Y02A50/30
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention is directed to inhibiting viral morphogenesis and viral infection. In particular, it concerns effecting such inhibition by inhibiting the prenylation or post prenylation reactions of a viral or host protein.

Claims

exact text as granted — not AI-modified
1 . A method to treat a viral infection in a subject via inhibiting the prenylation or a post-prenylation reaction of a protein contained in the virus infecting said subject, which method comprises administering to said subject an effective amount of an agent selected from the group consisting of
 a peptide that mimics the amino acid sequence of a “CXXX” (SEQ ID NO:1), ”XCXX” (SEQ ID NO:3), “XXCX” (SEQ ID NO:4), or “XXXC” (SEQ ID NO:5) box as it occurs in said viral protein,   an inhibitor of a prenyl transferase,   an inhibitor of an enzyme included in the pathway of a prenyl lipid synthesis from mevalonate,   a mimic of a prenyl group,   an inhibitor of a protease that removes the XXX tripeptide from the CXXX polypeptide following prenylation, a protease that removes the XX dipeptide from the XCXX polypeptide following prenylation, or a protease that removes the X residue from the XXCX polypeptide following prenylation, or a protease that removes a C-terminal domain of the prenylated protein including the entire CXXX box,   an inhibitor of prenyl cysteine methyltransferase, and   a combination thereof.   
     
     
         2 . The method of  claim 1 , wherein said agent is an inhibitor of an enzyme along the pathway of prenyl lipid synthesis from mevalonate. 
     
     
         3 . The method of  claim 1 , wherein said agent is a mimic of a prenyl group. 
     
     
         4 . The method of  claim 1 , wherein said agent is an inhibitor of a protease that removes the XXX tripeptide from the CXXX polypeptide following prenylation, a protease that removes the XX dipeptide from the XCXX polypeptide following prenylation, or a protease that removes the X residue from the XXCX polypeptide following prenylation or a protease that removes a C-terminal domain of the prenylated protein including the entire CXXX box. 
     
     
         5 . The method of  claim 1 , wherein said agent is an inhibitor of prenyl cysteine methyltransferase. 
     
     
         6 . The method of  claim 1 , wherein said subject is an animal or a plant. 
     
     
         7 . The method of  claim 1 , wherein said animal is a mammal. 
     
     
         8 . The method of  claim 7 , wherein said mammal is a human. 
     
     
         9 . The method of  claim 7 , wherein said mammal is a non-human primate. 
     
     
         10 . The method of  claim 1 , wherein said viral infection is caused by a virus selected from the group consisting of a double-strand DNA virus, a negative single-strand RNA virus, a positive single-strand RNA virus and a double-strand RNA virus. 
     
     
         11 . The method of  claim 10 , wherein said double-strand DNA virus is selected from the group consisting of a poxviridae, a herpesviridae and a papillomaviridiae. 
     
     
         12 . The method of  claim 10 , wherein said negative single-strand RNA virus is a bunyaviridiae. 
     
     
         13 . The method of  claim 10 , wherein said positive single-strand RNA virus is a hepatovirus. 
     
     
         14 . The method of  claim 10 , wherein said double-strand RNA virus is a reoviridiae. 
     
     
         15 . The method of  claim 1 , wherein said viral infection is caused by a virus selected from the group consisting of a pox virus, a bunyavirus, hepatitis E virus, human papilloma virus, molluscum contagiosum virus, vaccinia virus and reovirus. 
     
     
         16 . The method of  claim 15 , wherein said pox virus is smallpox virus. 
     
     
         17 . The method of  claim 15 , wherein said bunyavirus is oropouche virus. 
     
     
         18 . The method of  claim 1 , wherein said agent is administered with a pharmaceutically acceptable carrier or excipient. 
     
     
         19 . A kit to treat a viral infection in a subject via inhibiting the prenylation or a post-prenylation reaction of a protein contained in the virus infecting said subject, which kit comprises:
 a) an effective amount of an agent selected from the group consisting of   a peptide that mimics the amino acid sequence of a “CXXX” (SEQ ID NO:1), “XCXX” (SEQ ID NO:3), “XXCX” (SEQ ID NO:4), or “XXXC” (SEQ ID NO:5) box as it occurs in said viral protein,   an inhibitor of a prenyl transferase,   an inhibitor of an enzyme included in the pathway of a prenyl lipid synthesis from mevalonate,   a mimic of a prenyl group,   an inhibitor of a protease that removes the XXX tripeptide from the CXXX polypeptide following prenylation, a protease that removes the XX dipeptide from the XCXX polypeptide following prenylation, or a protease that removes the X residue from the XXCX polypeptide following prenylation, or a protease that removes a C-terminal domain of the prenylated protein including the entire CXXX box,   an inhibitor of prenyl cysteine methyltransferase, and   a combination thereof; and   b) an instruction for using said agent in treating said viral infection in said subject.   
     
     
         20 . A method to treat a viral infection in a subject via inhibiting the prenylation or a post-prenylation reaction of a host protein involved in life cycle of said infecting virus, which method comprises administering to said subject an effective amount of an agent selected from the group consisting of
 a peptide that mimics the amino acid sequence of a “CXXX” (SEQ ID NO:1), “XCXX” (SEQ ID NO:3), “XXCX” (SEQ ID NO:4), or “XXXC” (SEQ ID NO:5) box as it occurs in said viral protein,   an inhibitor of a prenyl transferase,   an inhibitor of an enzyme included in the pathway of a prenyl lipid synthesis from mevalonate,   a mimic of a prenyl group,   an inhibitor of a protease that removes the XXX tripeptide from the CXXX polypeptide following prenylation, a protease that removes the XX dipeptide from the XCXX polypeptide following prenylation, or a protease that removes the X residue from the XXCX polypeptide following prenylation, or a protease that removes a C-terminal domain of the prenylated protein including the entire CXXX box,   an inhibitor of prenyl cysteine methyltransferase, and   a combination thereof.

Join the waitlist — get patent alerts

Track US2008214471A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.